receptor agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
== Books == Anabolic Reference Guide. Mile High Publishing, 1991. Sports Supplement Review. Mile High Publishing, 1997. Body-for-LIFE: 12 Weeks to Mental and Physical Strength. HarperCollins, 1999. ISBN 0-06-019339-5 Body for Life Success Journal. HarperCollins, 2002. ISBN 0-06-051559-7 Eating for Life: Your Guide to Great Health, Fat Loss and Increased Energy! High Point Media, 2003. ISBN 0-9720184-1-7 Transformation: A Path from Physical to Spiritual Well-Being. Hay House, 2010. ISBN 978-1-4019-1176-8
1993/2629) Shropshire's Community Health Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2630) Hill Livestock (Compensatory Allowances) Regulations 1993 (S.I. 1993/2631) National Lottery etc. Act 1993 (Commencement No. 1 and Transitional Provisions) Order 1993 (S.I. 1993/2632) South East London Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2633) Haringey Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2634) North Staffordshire Combined Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2635) Lincoln District Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2636) Swindon and Marlborough National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2637) Louth and District Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2638) North Kent Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2639) Medway National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2640) Queen Victoria Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2641) Dartford and Gravesham National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2642) Worthing and Southlands Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2643) Gipsy Encampments (Borough of Holderness) Order 1993 (S.I. 1993/2644) Norfolk Mental Health Care National Health Service Trust (Establishment) Order 1993 (S.I.
Biological activities of metal ion-binding compounds can be changed in response to the increment of the metal concentration, and based on the latter compounds can be classified as "metal ionophores", "metal chelators" or "metal shuttles". If the biological effect is augmented by increasing the metal concentration, it is classified as a "metal ionophore". If the biological effect is decreased or reversed by increasing the metal concentration, it is classified as a "metal chelator". If the biological effect is not affected by increasing the metal concentration, and the compound-metal complex enters the cell, it is classified as a "metal shuttle". The term ionophore (from Greek ion carrier or ion bearer) was proposed by Berton Pressman in 1967 when he and his colleagues were investigating the antibiotic mechanisms of valinomycin and nigericin. Many ionophores are produced naturally by a variety of microbes, fungi and plants, and act as a defense against competing or pathogenic species. Multiple synthetic membrane-spanning ionophores have also been synthesized. The two broad classifications of ionophores synthesized by microorganisms are:
Sources: en.wikipedia.org
== Synthesis == Fentanyl is a 4-anilinopiperidine class synthetic opioid. The synthesis of Fentanyl is accomplished by one of four main methods as reported in the scientific literature: the Janssen, Siegfried, Gupta, or Suh method.
== Prognosis == Overall prognosis is dependent on the extent of cardiac dysfunction. Worse outcomes have been seen when echocardiography shows left ventricular wall thickness, poor systolic function and severe diastolic dysfunction. Light chain (AL-CM) Prognosis: For light-chain amyloidosis early detection leads to best possibility of therapies prolonging the period of remission. Well treated light chain cardiac amyloidosis has a 4-year survival rate of around 90%. In patients that undergo stem cell transplant the average survival time increases to 10 years. Staging systems have been developed to stratify severity of the disease, including the Mayo Biomarker Stage, which utilizes various biomarkers such as troponin I, troponin T, BNP, and NT-proBNP, and Free light chain concentrations. Familial (ATTRm-CM) Prognosis: Due to the extensive number of variables involved in this subtype, prognosis varies depending on the specific type of familial cardiac amyloidosis. Variables involve mutant vs wild type transthyretin mutation and age of onset of symptoms. In comparison to light chain amyloidosis, the familial subtype is slower to progress and has a more favorable prognosis. However, the Val 122lle mutation (most common cause of familial cardiac amyloidosis) has a 4-year survival rate of 16% with an average length of 26 months and is associated with a worse prognosis than wild type ATTR. A delay in recognition plays a major factor in this reduced survival rate.
Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth. Side effects of nemonapride include akathisia, dystonia, hypokinesia, tremor, hypersalivation, and hyperprolactinemia, among others. The drug acts as a dopamine D2, D3, and D4 receptor antagonist. To a lesser extent, it is also a serotonin 5-HT1A receptor partial agonist. Structurally, nemonapride is a benzamide derivative and is related to sulpiride and other benzamides. Nemonapride was introduced for medical use in either 1991 or 1997. It was developed and marketed by Yamanouchi Pharmaceuticals. The drug is approved only in Japan and China.
Sources: en.wikipedia.org
Just Stop Oil protesters vandalise Stonehenge by spraying the megaliths with orange cornflour powder paint. A police officer working as part of the prime minister's close protection team is suspended and later arrested as part of an ongoing investigation into bets on the date of the general election. BBC News reports that Laura Saunders, the Conservative candidate for Bristol North West, has become the second Conservative candidate to face an investigation by the Gambling Commission over betting on the date of the general election. It is subsequently reported that her husband, Tony Lee, the Conservative Party's campaigns director, is also being investigated by the commission. 20 June The Bank of England holds interest rates at 5.25%, its seventh consecutive freeze. Sunak says he is "incredibly angry" to learn of allegations that members of his party have betted on the date of the election, and that he will "boot out" anyone found to have broken the law. The number of people becoming ill from a recent outbreak of E. coli across the UK reaches 256, which includes 86 hospitalisations. The UK Health Security Agency reports that case numbers have now slowed, and that everything possible is being done to find the root cause, which may be pre-packaged sandwiches containing lettuce. 21 June Nigel Farage tells the BBC that he believes the Russo-Ukrainian War to have been precipitated by the West's eastward expansion of NATO and the European Union, but that the war itself is Vladimir Putin's fault.
== Management == There is no cure for Marfan syndrome, but life expectancy has increased significantly since the 1970s and is now similar to that of the average person. Regular checkups are recommended to monitor the health of the heart valves and the aorta. Marfan syndrome is treated by addressing each issue as it arises and, in particular, preventive medication even for young children to slow progression of aortic dilation. The goal of this treatment strategy is to slow the progression of aortic dilation and prevent any damage to heart valves by eliminating heart arrhythmias, minimizing the heart rate, and lowering the person's blood pressure.
== Sources == This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from World Food and Agriculture – Statistical Yearbook 2025, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2026, Food and Agriculture Organization of the United Nations.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.